ESTRO 2020 Abstract book

S645 ESTRO 2020

plus concomitant chemotherapy with Cisplatin weekly and intracavitary BT. GEC ESTRO recommends the use image-based brachytherapy and Retro-EMBRACE and EMBRACE, which will establish MRI-guided brachytherapy as a gold standard. Material and Methods From October 2015 to May 2019 forty four patients with cervical cancerstages I-IV, underwent definitive treatment. Patients were subjected to MRI based brachytherapy post EBRT using GEC ESTRO working group guidelines. Median age was 55 years (29-80). Histology was squamous cell carcinoma 66% and adenocarcinoma 34%. The clinical stage was: IB2 7%, II 57%, III 27%, IV A 2%, IVB 7%. The median tumor size 45 mm (7-70).All patients received EBRT plus intracavitary brachytherapy whit UTRECHT applicator, except a patient who treated with DOME applicator by the impossibility cervical dilation. Median dose EBRT 50.4 (45- 60), median dose BT 28 (19.5-28), median dose EQD2 total (α/β=10) (EBRT+BT) was 88 Gy (76-96), median dose HR-CVTD90 (α/β=10) 90.5 Gy ( 70-114) and IR-CVTD90 68Gy (56-80). The median dose organs at risk (OAR) D2cc EQD2 (α/β=3): bladder 74Gy (50-91), rectum 65Gy (48-77) and sigma 63 Gy. The overall treatment time was ≥8 weeks in 98% of the patients with a median overall treatment time of 82 days (55-129). Toxicity were evaluated by CTCAE v4.0. Local Control (LC), Disease Free Survival (DFS) and Overall Survival (OS) were estimated using the Kaplan-Meier method. All statistical analyses were performed using IBM SPSS Statistics version 21.0. Results Complete response confirmed by MRI in 82% of the patients. With a median follow-up of 28 months local control was 95.5%, 75 % patients didn't have a relapse. The first relapse was Local recurrence 2%, Pelvic recurrence 2%, Local and regional recurrence 4.5% and distant metastasis 16%. The 3-year LC, DFS and OS rates were 97%, 72% and 88% respectively and the 3-year LC rates by stages rates was I- IIB 100%, III 91%, DFS was 67% in IB, 100% IIA, 83% IIB, 74% III and IV 67%; and OS by stages rates was I- IIB 100%, III 74%, IV 66%. Prevalence rates of acute toxicity intestinal were G1 16%; rectal acute toxicity was G1 20%, G2 7%, G3 2% (1 patient) and bladder acute toxicity was G1 11%. Prevalence rates of chronic toxicity intestinal were G1 2%, bladder chronic toxicity G1 4.5%, G2 2% and rectal chronic toxicity G1 4.5%, G2 2%, G3 4.5% (2 patients). We have not observed G3 toxicity intestinal or bladder. Conclusion Our results show that HDR-BT MRI based IGABT allows doses to be administered >90 Gy to HDR-CTV getting a good LC whit acceptable toxicity. We need to get better the overall treatment time. PO-1133 Concurrent chemoradiotherapy with or without brachytherapy; a retrospective clinical study B. Khadidja 1 , Z. Benyoucef 1 , S. Sebti 1 , L. Hamzi 1 , F. Boulekhsaim 2 , H. Boukabous 2 , S. Khalfa 2 , M. Zarroug 2 , Z. Griballah 2 , S. Toukal 2 , S. Khoudri 3 1 CLCC Mokhtari Abdelghani- Faculty of Medicine- University Farhat Abes Setif 1, Radiation oncologist, Setif, Algeria ; 2 CLCC Mokhtari Abdelghani Setif, Radiation oncologist, Setif, Algeria ; 3 CLCC Mokhtari Abdelghani- University Farhat Abes Setif 1, Radiation oncologist, Setif, Algeria

External beam radiotherapy (EBRT) combined at brachytherapy (ICBT) are well established as the standard radical radiotherapy (RT) for cervical cancer. However, in our department brachytherapy is not available, patients who could not move to another anti-cancer center which is about 1000 km, received EBRT alone with three- dimensional conformal radiotherapy (3DCRT). The purpose of this study is to evaluate the results of EBRT with or without ICBT for patients with cervical cancer. Material and Methods 95 patients with cervical carcinoma (stage: IIb to IV) were treated with concurrent chemoradiation (3DCRT) with or without brachytherapy, between 2014 and 2018. there were 88 squamous cell carcinoma, and 7 adenocarcinomas. The median patient age was 60 years, ranging from 37 to 85 years. 63 IIb, 15III (8IIIA, 7IIIB) and 17 IV. Only 14 patients were benefited to ICBT. A dose of 66 Gy was delivered in 36 cases, 39 patients received 60Gy, by conventional fractionation without intracavitary brachytherapy. Only 14 patients received EBRT followed by intra cavitary brachytherapy. Results The 3-year overall survival (OAS) and local control (LC) rates were 65.3% and 75.7% respectively. The 3-year overall survival (OAS) was 71.4% for the EBRT with ICBT group, 64.2% for the External Beam Boost without ICBT group (P=0.031) . Conclusion Pelvic EBRT in combination with vaginal brachytherapy, in cervical cancer patients had a reduced risk of locoregional recurrence without increased side effects compared with patients treated with pelvic EBRT and External Beam Boost without vaginal brachytherapy. PO-1134 18F-FDG-PET/CT role in the adjuvant setting of endometrial cancer M. Ferioli 1 , V. Panni 1 , A. Galuppi 2 , A. Zamagni 1 , M. Buwenge 1 , G. Macchia 3 , F. Deodato 3 , A. Re 3 , M. Boccardi 3 , S. Cilla 4 , S. Fanti 5 , A.G. Morganti 1 , S. Cammelli 1 1 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Radiation Oncology Unit- Department of Experimental- Diagnostic and Specialty Medicine DIMES, Bologna, Italy ; 2 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Radiation Oncology Unit, Bologna, Italy ; 3 Giovanni Paolo II Foundation- Campobasso- Italy, Radiotherapy Unit- General Oncology Unit - Università Cattolica del Sacro Cuore, Campobasso, Italy ; 4 Giovanni Paolo II Foundation- Campobasso- Italy, Medical Physics Unit- Università Cattolica del Sacro Cuore, Campobasso, Italy ; 5 Sant'Orsola-Malpighi Hospital- University of Bologna- Bologna- Italy, Nuclear Medicine Unit- Department of Experimental- Diagnostic and Specialty Medicine DIMES, Bologna, Italy Purpose or Objective Endometrial cancer is surgically staged, and while surgery is the primary treatment modality, the identification of disease extent - in particular extrauterine spread - prior to surgery is important to optimize the treatment decision making. Aim of this study was to define the role of 18- Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT) in the adjuvant treatment of high-risk endometrial cancer (HR-EC) defined based on FIGO stage, histotype, grading and performed lymphadenectomy. Material and Methods HR-EC patients referred to our radiation therapy centre between 2008 and 2018 that had been treated by surgery and had performed a postoperative 18F-FDG- PET/CT exam were included in the study. The primary endpoint was to investigate the role of 18F-FDG-PET/CT in changing indication and type of HR-EC adjuvant treatment. Results

Purpose or Objective